Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Toll-like receptors
Research
George Church launches startup aimed at safer gene therapy
A Harvard team led by George Church founded Ally Therapeutics to develop a way to "cloak" viral vectors from immune surveillance.
Angus Liu
Feb 10, 2021 2:00pm
Stopping cancer before it develops
Jun 5, 2019 2:00pm
Idera’s TLR9-Yervoy combo works in PD-1-refractory melanoma
Dec 14, 2018 10:48am
Targeting Alzheimer’s with a soluble toll-like receptor
Aug 29, 2018 10:19am
Checkmate's I-O combo reverses PD-1 resistance in melanoma
Apr 17, 2018 9:37am
Targeting a toll-like receptor could attack the root cause of lupus
Jan 26, 2018 3:25pm
